ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated. If you have any questions, please contact Marianne Reed at mreed@ku.edu .

Show simple item record

dc.contributor.authorChittasupho, Chuda
dc.contributor.authorManikwar, Prakash
dc.contributor.authorKrise, Jeffrey P.
dc.contributor.authorSiahaan, Teruna J.
dc.contributor.authorBerkland, Cory J.
dc.date.accessioned2017-05-08T18:41:55Z
dc.date.available2017-05-08T18:41:55Z
dc.date.issued2010-02-01
dc.identifier.citationChittasupho, C., Manikwar, P., Krise, J. P., Siahaan, T. J., & Berkland, C. (2010). cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Molecular Pharmaceutics, 7(1), 146. http://doi.org/10.1021/mp900185uen_US
dc.identifier.urihttp://hdl.handle.net/1808/24022
dc.description.abstractLeukocyte function associated antigen-1 (LFA-1) is a primary cell adhesion molecule of leukocytes required for mediating cellular transmigration into sites of inflammation via the vascular endothelium. A cyclic peptide, cIBR, possesses high affinity for LFA-1 and conjugation to the surface of poly(dl-lactic-co-glycolic acid) nanoparticles can specifically target and deliver the encapsulated agents to T cells expressing LFA-1. The kinetics of targeted nanoparticle uptake by acute lymphoblastic leukemia T cells was investigated by flow cytometry and microscopy and compared to untargeted nanoparticles. The specificity of targeted nanoparticles binding to the LFA-1 integrin was demonstrated by competitive inhibition using free cIBR peptide or using the I domain of LFA-1 to inhibit the binding of targeted nanoparticles. The uptake of targeted nanoparticles was concentration and energy dependent. The cIBR-conjugated nanoparticles did not appear to localize with lysosomes whereas untargeted nanoparticles were detected in lysosomes in 6 hrs and steadily accumulated in lysosomes for 24 hrs. Finally, T-cell adhesion to epithelial cells was inhibited by cIBR-nanoparticles. Thus, nanoparticles displaying the cIBR ligand may offer a useful targeted drug delivery system as an alternative treatment of inflammatory diseases involving transmigration of leukocytes.en_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://doi.org/10.1021/mp900185u.en_US
dc.subjectLFA-1en_US
dc.subjectLeukocytesen_US
dc.subjectPeptideen_US
dc.subjectNanoparticlesen_US
dc.subjectTargetingen_US
dc.titlecIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cellsen_US
dc.typeArticleen_US
kusw.kuauthorChittasupho, Chuda
kusw.kuauthorManikwar, Prakash
kusw.kuauthorKrise, Jeffrey P.
kusw.kuauthorSiahaan, Teruna J.
kusw.kuauthorBerkland, Cory J.
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.1021/mp900185uen_US
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC2815130en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record